PE20040193A1 - Formulaciones inyectables de bifosfonatos - Google Patents

Formulaciones inyectables de bifosfonatos

Info

Publication number: PE20040193A1
Authority: PE; Peru
Prior art keywords: bisodium; acid; divaldonate; biphosphonate; injectable
Prior art date: 2002-05-13

Application number

PE2003000440A

Other languages

English (en)

Spanish (es)

Inventor

Andrea Capocchi

Annamaria Soliani Raschini

Rossella Musa

Original Assignee

Chiesi Farma Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-05-13

Filing date

2003-05-06

Publication date

2004-05-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27639074&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20040193(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-05-06 Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa

2004-05-31 Publication of PE20040193A1 publication Critical patent/PE20040193A1/es

Links

239000000203 mixture Substances 0.000 title abstract 2
239000002253 acid Substances 0.000 abstract 3
208000010191 Osteitis Deformans Diseases 0.000 abstract 1
208000001132 Osteoporosis Diseases 0.000 abstract 1
208000027868 Paget disease Diseases 0.000 abstract 1
210000000988 bone and bone Anatomy 0.000 abstract 1
HJKBJIYDJLVSAO-UHFFFAOYSA-L clodronic acid disodium salt Chemical compound [Na+].[Na+].OP([O-])(=O)C(Cl)(Cl)P(O)([O-])=O HJKBJIYDJLVSAO-UHFFFAOYSA-L 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
159000000011 group IA salts Chemical class 0.000 abstract 1
238000007918 intramuscular administration Methods 0.000 abstract 1
229960004393 lidocaine hydrochloride Drugs 0.000 abstract 1
YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 abstract 1
208000027202 mammary Paget disease Diseases 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
CAKRAHQRJGUPIG-UHFFFAOYSA-M sodium;[4-azaniumyl-1-hydroxy-1-[hydroxy(oxido)phosphoryl]butyl]-hydroxyphosphinate Chemical compound [Na+].NCCCC(O)(P(O)(O)=O)P(O)([O-])=O CAKRAHQRJGUPIG-UHFFFAOYSA-M 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Orthopedic Medicine & Surgery (AREA)
Engineering & Computer Science (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Inorganic Chemistry (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

PE2003000440A 2002-05-13 2003-05-06 Formulaciones inyectables de bifosfonatos PE20040193A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IT2002TO000406A ITTO20020406A1 (it)	2002-05-13	2002-05-13	Formulazioni di bisfosfonati ad uso iniettabile.

Publications (1)

Publication Number	Publication Date
PE20040193A1 true PE20040193A1 (es)	2004-05-31

Family

ID=27639074

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PE2003000440A PE20040193A1 (es)	2002-05-13	2003-05-06	Formulaciones inyectables de bifosfonatos

Country Status (5)

Country	Link
AR (1)	AR040001A1 (it)
AU (1)	AU2003240225A1 (it)
IT (1)	ITTO20020406A1 (it)
PE (1)	PE20040193A1 (it)
WO (1)	WO2003094925A1 (it)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2006012700A1 (en) *	2004-08-04	2006-02-09	Team Health Pty Ltd	Method of treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1187828B (it) *	1985-05-24	1987-12-23	Gentili Ist Spa	Composizione farmaceutica a base di difosfonati per il trattamento dell aretrosi
US5462932A (en) *	1994-05-17	1995-10-31	Merck & Co., Inc.	Oral liquid alendronate formulations
IT1296495B1 (it) *	1997-11-21	1999-06-25	Prodotti Antibiotici Spa	Impiego di bisfosfonati nella preparazione di forme farmaceutiche per somministrazione intramuscolare
US6677320B2 (en) *	2000-01-20	2004-01-13	Hoffmann-La Roches Inc.	Parenteral bisphosphonate composition with improved local tolerance
EP1136069A1 (en) *	2000-03-21	2001-09-26	SPA SOCIETA' PRODOTTI ANTIBIOTICI S.p.A.	Pharmaceutical compositions containing clodronates for high local tolerance intramuscular administration

2002
- 2002-05-13 IT IT2002TO000406A patent/ITTO20020406A1/it unknown
2003
- 2003-05-06 PE PE2003000440A patent/PE20040193A1/es not_active Application Discontinuation
- 2003-05-12 AR ARP030101639A patent/AR040001A1/es unknown
- 2003-05-12 AU AU2003240225A patent/AU2003240225A1/en not_active Abandoned
- 2003-05-12 WO PCT/EP2003/004934 patent/WO2003094925A1/en not_active Ceased

Also Published As

Publication number	Publication date
AR040001A1 (es)	2005-03-09
AU2003240225A1 (en)	2003-11-11
WO2003094925A1 (en)	2003-11-20
ITTO20020406A0 (it)	2002-05-13
ITTO20020406A1 (it)	2003-11-13

Similar Documents

Publication	Publication Date	Title
ES2244831T5 (es)	2016-05-10	Uso de pantenol y/o ácido pantoténico y ácido hialurónico y/o hialuronato para la producción de una composición farmacéutica para aplicación oftalmológica
RU2008138266A (ru)	2010-03-27	Составы для парентерального введения лекарств и их применения
NO20081889L (no)	2008-04-21	Fast vaksine formulering
ATE538774T1 (de)	2012-01-15	Pharmazeutische formulierungen und verfahren zur behandlung von atemwegsinfektionen
DOP2006000192A (es)	2007-03-31	Formulaciones de ibandronato mejoradas
AR046773A1 (es)	2005-12-21	Formulaciones farmaceuticas de bisfosfonatos
US20150080347A9 (en)	2015-03-19	Liquid formulations
PE20081150A1 (es)	2008-10-03	Inhibidores de dipetidilpeptidasa
ES2190244T3 (es)	2003-07-16	Uso de la hormona paratiroidea constituida por una secuencia de aminoacidos 1-34 de la hormona paratiroidea humana para reducir el riesco de fracturas oseas vertebrales y no vertebrales.
CY1106482T1 (el)	2012-01-25	Φαρμακευτικη παρεντepικη συνθεση πepιεχοντας ενα διφωσφονικο
CO5390076A1 (es)	2004-04-30	Composiciones farmaceuticas
RU2011122629A (ru)	2012-12-20	Водная композиция, содержащая фолликулостимулирующий гормон
CO6180498A2 (es)	2010-07-19	Una composicion de liberacion sostenida que comprende un peptido fisiologicamente activo soluble en agua dispersado uniformemente en una microcapsula
AR055363A1 (es)	2007-08-22	Formulaciones farmaceuticas que comprenden un beta 2- agonista de accion prolongada para administracion por nebulizacion
BR0008509A (pt)	2002-02-05	Composição farmacêutica oral estabilizada contendo iodeto e iodato e método
SE9801495D0 (sv)	1998-04-28	Protein formulationa
ECSP044961A (es)	2004-03-23	Acido n-(5-clorosaliciloil)-8-aminocaprilico como agente de suministro oral para fragmentos de hormona paratiroides
EA200900095A1 (ru)	2009-08-28	Лекарственные формы бифосфонатов для ингаляции и способы их применения
DE602004020488D1 (de)	2009-05-20	Mikroemulsionen von retinoiden und diese enthaltende pharmazeutische zusammensetzungen
PE20040193A1 (es)	2004-05-31	Formulaciones inyectables de bifosfonatos
ECSP088285A (es)	2008-04-28	3-(2-dimetilaminometil ciclohexil) fenol formulación retardada.
ES2262145T3 (es)	2006-11-16	Composicion anabolica para la masa osea que comprende olpadronato.
ES2251226T3 (es)	2006-04-16	Utilizacion de derivados de acido bisfosfonico para la preparacion de un medicamento destinado al tratamiento de la cojera.
AR022462A1 (es)	2002-09-04	Uso de un agente que disminuye el colesterol
ES2726401T3 (es)	2019-10-04	Uso de inhibidores de HDAC para el tratamiento de la destrucción ósea

Legal Events

Date	Code	Title	Description
2006-05-11	FC	Refusal